
KALV
Healthcare · Biotechnology · $1.44B market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2026
EPS trend, 90 days to now · +24.3% over 90 days · 30-day revisions 4 up, 2 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 25, 2026 | After the close | -0.53 | 0.94 | +277.4% |
| Dec 11, 2025 | Before the open | -0.91 | -0.92 | -1.1% |
| Sep 3, 2025 | Before the open | -0.90 | -1.12 | -24.4% |
| Jul 10, 2025 | Before the open | -0.81 | -0.99 | -22.2% |
| Mar 12, 2025 | Before the open | -0.87 | -0.92 | -5.7% |
| Dec 4, 2024 | After the close | -0.91 | -0.91 | 0.0% |
| Sep 5, 2024 | After the close | -0.94 | -0.87 | +7.4% |
| Jul 11, 2024 | Before the open | -0.73 | -1.02 | -39.7% |
| Mar 11, 2024 | After the close | -0.80 | -0.84 | -5.0% |
| Dec 7, 2023 | After the close | -0.78 | -0.80 | -2.6% |
| Sep 7, 2023 | After the close | -0.84 | -0.74 | +11.9% |
| Jul 7, 2023 | Before the open | -0.94 | -0.77 | +18.1% |
| Mar 9, 2023 | After the close | -1.00 | -0.75 |
As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista…
| +25.0% |
| Dec 8, 2022 | After the close | -1.05 | -0.90 | +14.3% |
| Sep 8, 2022 | After the close | -0.97 | -0.94 | +3.1% |
| Jul 7, 2022 | Before the open | -1.09 | -0.98 | +10.1% |
| Mar 10, 2022 | After the close | -0.90 | -0.92 | -2.2% |
| Dec 9, 2021 | After the close | -0.75 | -0.80 | -6.7% |
| Sep 9, 2021 | Before the open | -0.71 | -0.66 | +7.0% |
| Jul 13, 2021 | After the close | -0.54 | -0.67 | -24.1% |
| Mar 11, 2021 | After the close | -0.59 | -0.56 | +5.1% |
| Dec 10, 2020 | After the close | -0.66 | -0.58 | +12.1% |
| Sep 14, 2020 | After the close | -0.55 | -0.61 | -10.9% |
| Jun 28, 2020 | After the close | -0.61 | -0.37 | +39.3% |
| Mar 10, 2020 | Before the open | -0.52 | -0.52 | 0.0% |
| Dec 3, 2019 | Before the open | -0.54 | -0.33 | +38.9% |
| Sep 9, 2019 | Before the open | -0.58 | -0.42 | +27.6% |
| Jul 15, 2019 | Before the open | -0.42 | -0.49 | -16.7% |
| Mar 14, 2019 | Before the open | -0.46 | -0.23 | +50.0% |
| Dec 14, 2018 | Before the open | -0.42 | -0.22 | +47.6% |
| Sep 14, 2018 | Before the open | -0.33 | -0.47 | -42.4% |
| Jul 30, 2018 | After the close | -0.35 | -0.06 | +82.9% |
| Mar 16, 2018 | Before the open | -0.13 | -0.49 | -276.9% |